stride semaglutide STRIDE - Semaglutide - STRIDEclinical trial locations improved walking capacity and quality-of-life STRIDE Trial: Semaglutide Enhances Walking Capacity in Peripheral Artery Disease and Type 2 Diabetes

STRIDEtrial NPH The STRIDE trial has provided significant evidence for the positive impact of semaglutide on individuals suffering from symptomatic peripheral artery disease (PAD) and type 2 diabetes. This large-scale, multinational, double-blind, and randomized clinical trial, designated as NCT04560998, has demonstrated that semaglutide can substantially improve walking capacity, alleviate symptoms, and enhance overall quality of life for this patient population.

Understanding Peripheral Artery Disease and Type 2 Diabetes:

Peripheral artery disease (PAD) is a circulatory condition characterized by the narrowing of arteries, most commonly in the legs, which reduces blood flow.2025年3月31日—Semaglutide is the first drug in patients with PAD and type 2 diabetesshown to improve walking capacity, symptoms, and quality of life. This often leads to leg pain, cramping, and difficulty walking, particularly during activity. Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose), leading to an excess of sugar in the blood. It is well-established that these two conditions frequently coexist, and their combined presence can lead to significant health complications and diminished functional capacity.

The STRIDE Trial: Design and Objectives:

The STRIDE trial was meticulously designed as a double-blind, randomised, placebo-controlled trial, adhering to the highest scientific standardsOzempic® (semaglutide) injection 1 mg showed improved .... Conducted across 112 outpatient clinical trial sites in 20 countries in North America and beyond, the study enrolled participants with symptomatic PAD and type 2 diabetes. The trial specifically evaluated the effects of once-weekly subcutaneous semaglutide 1.0 mg compared to a placebo. The primary outcome measured was pain-free walking distance, a crucial indicator of functional ability in individuals with PAD.Semaglutide Shows Major Benefits in PAD: STRIDE The trial was a phase 3b clinical trial, indicating a robust evaluation of the drug's efficacy and safety.

Key Findings: Semaglutide's Impact on Walking and Quality of Life:

The results emerging from the STRIDE trial have been highly encouraging. A significant finding is that semaglutide significantly improves function, symptoms, and health-related QoL in patients with symptomatic PAD and T2DM. Specifically, the research indicated that semaglutide increased walking distance in patients with symptomatic PAD and type 2 diabetes.Ozempic® (semaglutide) injection 1 mg showed improved functional ... This improvement was observed across various participant groups, including individuals without obesity and those with well-controlled HbA1c levels.

Further analysis of the STRIDE trial data confirms the potential impact of semaglutide on quality-of-life metrics for PAD patients with diabetes.Benefit of Semaglutide in Symptomatic Peripheral Artery ... The drug has been shown to have significantly improved walking outcomes in people with PAD and diabetesOzempic® (semaglutide) injection 1 mg showed improved .... This translates to a tangible improvement in daily life, allowing individuals to move with less discomfort and greater ease.

Moreover, semaglutide has demonstrated significantly improved walking distance, symptoms and quality of life in the trial participants. This comprehensive improvement addresses not only the physical limitations but also the associated emotional and psychological burden that often accompanies chronic conditions. The STRIDE trial offers strong evidence that semaglutide, available under brand names such as Ozempic and Wegovy, can significantly improve walking capacity in people living with both PAD and type 2 diabetes.

Semaglutide: A Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA):

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). GLP-1 RAs are a class of medications that mimic the effects of a natural hormone in the body that helps regulate blood sugar. While often used for glycemic control in patients with type 2 diabetes, the STRIDE trial highlights its expanded therapeutic potential. The drug is approved as an adjunct to diet and exercise for improving glycemic control in patients with type 2 diabetessemaglutide in peripheral artery disease and type 2 diabetes.

Broader Implications and Future Directions:

The STRIDE trial analysis confirms that semaglutide offers a new and effective option for patients experiencing symptomatic peripheral artery disease and type 2 diabetes. It is noteworthy that semaglutide is the first drug in patients with PAD and type 2 diabetes shown to improve walking capacity, symptoms, and quality of life.STRIDE Poster This represents a significant advancement in the management of this challenging condition.

The trial also demonstrated sex differences in the effectiveness of semaglutide in patients with PAD and type 2 diabetes, suggesting potential tailored approaches to treatment in the future. While pain-free walking distance was a primary outcome, continued research may explore other metrics and long-term benefitsSemaglutideis a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved as an adjunct to diet and exercise for glycemic control in patients with..

The STRIDE trial results indicate that semaglutide 1 mg resulted in a 13% greater improvement in maximum walking distance compared to placebo. This statistically significant finding underscores the clinical relevance of the treatment.STRIDE: Semaglutide and Walking Capacityin People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes. Print; Share. In summary, semaglutide has significantly improved walking capacity and quality-of-life, offering a promising therapeutic avenue for individuals battling the debilitating effects of peripheral artery disease and type 2 diabetes作者：MP Bonaca·2025·被引用次数：109—STRIDE was a double-blind, randomised, placebo-controlled trialdone at 112 outpatient clinical trial sites in 20 countries in North America, .... The STRIDE trial has paved the way for a better understanding and management of these interconnected health issues.Ozempic® (semaglutide) injection 1 mg showed improved functional ...